And then there is this, http://www.aidsmap.com/Hepatitis-C-virus-reinfection-is-uncommon-after-being-cured-with-DAAs/page/3139853/ by research scientists, undermining the Cochrane review…..maybe the Cochrane review could investigate good barbecue recipes, I am curious what is effective.

Professor Ed Gane chimes in:

https://www.nzdoctor.co.nz/news/2017/june-2017/14/cochrane-comes-down-hard-on-hep-c–drug-trials,-calls-%E2%80%98cure%E2%80%99-a-misnomer.aspx

A response from the AASLD:

AASLD and IDSA would like to express our serious concerns regarding the recent Cochrane Group Review concluding that there is a lack of valid evidence supporting the benefit of direct acting antiviral (DAA) therapy for chronic infection with hepatitis C virus (HCV), and its supposition: “the possibility of potentially harming people with chronic hepatitis ought to be considered before treating people with hepatitis C with DAAs.” Our review of this Cochrane publication suggests significant flaws in this analysis, yielding a misleading and a harmful conclusion.

and

……even early data from the DAA experience support clear improvements in clinical outcomes that can be measured in the short term. Cure of HCV infection immediately reduces symptoms and organ dysfunction from severe extrahepatic manifestations including cryoglobulinemic vasculitis, a complication affecting up to 10 percent of HCV-infected patients.

https://www.aasld.org/about-aasld/press-room/aasld-expresses-concern-cochrane-review-daas

Edit: EASL have also responded along similar lines:

“EASL, the European Association for the Study of the Liver, one of the world leading associations of liver specialists, feels compelled to express its serious concerns after the recent publication of a Cochrane Group systematic review entitled “Direct acting antivirals for chronic hepatitis C” by Jakobsen et al.”

http://www.journal-of-hepatology.eu/pb/assets/raw/Health%20Advance/journals/jhepat/CochraneEASLJMP003.pdf